MAIA Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About MAIA Interactive Breakdown Better Bets vs. MAIA Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    MAIA Biotechnology (MAIA)

    Market Price (9/21/2026): $1.34 | Market Cap: $81.5 MilSector: Health Care | Industry: Biotechnology

    MAIA Biotechnology (MAIA)

    Market Price (9/21/2026): $1.34
    Market Cap: $81.5 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -93%, 3Y Excs Rtn is -95%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -28 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38%

    Key risks
    MAIA key risks include [1] the potential failure of its pivotal THIO clinical trials for non-small cell lung cancer and [2] a limited 8-month cash runway necessitating continuous and potentially dilutive fundraising.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -93%, 3Y Excs Rtn is -95%
    3 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -28 Mil
    5 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38%
    6 Key risks
    MAIA key risks include [1] the potential failure of its pivotal THIO clinical trials for non-small cell lung cancer and [2] a limited 8-month cash runway necessitating continuous and potentially dilutive fundraising.

    MAIA in ETFs

    Weight = MAIA's share of each fund

    VTI0.00%

    Valuation & Metrics

    FYE: 12/31MAIA [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$65.0 Mil—
    FY 2027 Sales$66.3 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth2.0%12.9%
    EARNINGS
    LTM Net Income (GAAP) [3]$-26.8 Mil—
    FY 2026 Net Income (Non-GAAP)$-17.3 Mil—
    FY 2027 Net Income (Non-GAAP)$-15.4 Mil—
    FY 2027 Net Income Growth—18.1%
    FY 2026 EPS (Non-GAAP)$-0.54—
    FY 2027 EPS (Non-GAAP)$-0.48—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S1.31.6
    FY 2027 P/S1.2—
    FY 2026 P/E—7.4
    FY 2027 P/E——

    [1] MAIA forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Issued Patents Globally108132025Link
    Number of Pending Patent Applications248132025Link
    Number of Clinical Trials211072025Link
    Lead Program (THIO-101) Median Overall Survival (in months)17.86052025Link
    Number of Employees1311072025Link
    Number of Drug Candidates in Pipeline511072025Link

    Price Chart

    null
    Upcoming
    11/06/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/18/2026

    MAIA Biotechnology (MAIA) stock has lost about 5% since 5/31/2026 because of the following key factors:

    1. MAIA Biotechnology reported a wider net loss in its fiscal Q2 2026.

    The company announced its fiscal Q2 2026 earnings on August 10, 2026, reporting a net loss of USD 7.94 million, which translated to a basic loss of USD 0.13 per share. This performance missed analysts' consensus estimate of a USD 0.11 loss per share by USD 0.02. This net loss also represented an increase compared to the USD 5.35 million loss reported in Q2 2025.

    2. The company remains in a clinical stage without revenue-generating products.

    As a clinical-stage biopharmaceutical company, MAIA Biotechnology currently has no approved products or revenue-generating therapies on the market. This status means the company continues to operate at a significant net loss, with a trailing 12-month net profit of -$26.85 million ending June 30, 2026. While the company maintains a strong balance sheet with no debt and ample liquidity, the absence of commercial revenue weighs on investor sentiment.

    Show more
    Updated on 9/18/2026

    MAIA Biotechnology (MAIA) stock has lost about 5% since 5/31/2026 because of the following key factors:

    1. MAIA Biotechnology reported a wider net loss in its fiscal Q2 2026.

    The company announced its fiscal Q2 2026 earnings on August 10, 2026, reporting a net loss of USD 7.94 million, which translated to a basic loss of USD 0.13 per share. This performance missed analysts' consensus estimate of a USD 0.11 loss per share by USD 0.02. This net loss also represented an increase compared to the USD 5.35 million loss reported in Q2 2025.

    2. The company remains in a clinical stage without revenue-generating products.

    As a clinical-stage biopharmaceutical company, MAIA Biotechnology currently has no approved products or revenue-generating therapies on the market. This status means the company continues to operate at a significant net loss, with a trailing 12-month net profit of -$26.85 million ending June 30, 2026. While the company maintains a strong balance sheet with no debt and ample liquidity, the absence of commercial revenue weighs on investor sentiment.

    3. Investor caution persists due to the long development timelines for its lead candidate.

    Despite several positive updates regarding its lead investigational candidate, ateganosine (THIO), including strong initial efficacy data from the Phase 2 THIO-101 Part C Expansion Trial in third-line non-small cell lung cancer (NSCLC) in July 2026, and the initiation of its Phase 2 expansion in the U.S. in September 2026, the market may be reflecting the inherently long and uncertain timelines for drug development and commercialization. The time horizon for profitability remains distant, which can lead to a more cautious stock movement even with favorable clinical progress.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -5.8% change in MAIA stock from 5/31/2026 to 9/20/2026 was primarily driven by a -25.6% change in the company's Shares Outstanding (Mil).
    (LTM values as of)53120269202026Change
    Stock Price ($)1.391.31-5.8%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)4561-25.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    5/31/2026 to 9/20/2026
    ReturnCorrelation
    MAIA-5.8% 
    Market (SPY)0.9%41.0%
    Sector (XLV)12.7%8.0%

    Fundamental Drivers

    The -42.0% change in MAIA stock from 2/28/2026 to 9/20/2026 was primarily driven by a -45.4% change in the company's Shares Outstanding (Mil).
    (LTM values as of)22820269202026Change
    Stock Price ($)2.261.31-42.0%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)3361-45.4%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    2/28/2026 to 9/20/2026
    ReturnCorrelation
    MAIA-42.0% 
    Market (SPY)11.6%40.1%
    Sector (XLV)5.5%14.9%

    Fundamental Drivers

    The -14.9% change in MAIA stock from 8/31/2025 to 9/20/2026 was primarily driven by a -50.2% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120259202026Change
    Stock Price ($)1.541.31-14.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)3061-50.2%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2025 to 9/20/2026
    ReturnCorrelation
    MAIA-14.9% 
    Market (SPY)19.4%25.3%
    Sector (XLV)24.1%12.3%

    Fundamental Drivers

    The -25.1% change in MAIA stock from 8/31/2023 to 9/20/2026 was primarily driven by a -78.8% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120239202026Change
    Stock Price ($)1.751.31-25.1%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1361-78.8%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2023 to 9/20/2026
    ReturnCorrelation
    MAIA-25.1% 
    Market (SPY)75.6%14.4%
    Sector (XLV)32.3%10.8%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    MAIA Return--21%-67%69%-23%-8%-69%
    Peers Return-13%5%-7%-12%-34%77%-13%
    S&P 500 Return27%-19%24%23%16%12%103%

    Monthly Win Rates [3]
    MAIA Win Rate-50%42%33%25%56% 
    Peers Win Rate50%44%48%46%40%51% 
    S&P 500 Win Rate75%42%67%75%67%44% 

    Max Drawdowns [4]
    MAIA Max Drawdown---83%-62%-65%-59% 
    Peers Max Drawdown-47%-47%-53%-55%-65%-38% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: GERN, TELO, AGEN, IOVA, REGN.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/18/2026 (YTD)

    How Low Can It Go

    EventMAIAS&P 500
    2025 US Tariff Shock
      % Loss-23.0%-18.8%
      % Gain to Breakeven29.9%23.1%
      Time to Breakeven14 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-63.9%-9.5%
      % Gain to Breakeven177.1%10.5%
      Time to Breakeven104 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-50.9%-6.7%
      % Gain to Breakeven103.8%7.1%
      Time to Breakeven344 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-30.5%-24.5%
      % Gain to Breakeven43.9%32.4%
      Time to Breakeven92 days427 days

    Compare to GERN, TELO, AGEN, IOVA, REGN

    In The Past

    MAIA Biotechnology's stock fell -23.0% during the 2025 US Tariff Shock. Such a loss loss requires a 29.9% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventMAIAS&P 500
    2025 US Tariff Shock
      % Loss-23.0%-18.8%
      % Gain to Breakeven29.9%23.1%
      Time to Breakeven14 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-63.9%-9.5%
      % Gain to Breakeven177.1%10.5%
      Time to Breakeven104 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-50.9%-6.7%
      % Gain to Breakeven103.8%7.1%
      Time to Breakeven344 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-30.5%-24.5%
      % Gain to Breakeven43.9%32.4%
      Time to Breakeven92 days427 days

    Compare to GERN, TELO, AGEN, IOVA, REGN

    In The Past

    MAIA Biotechnology's stock fell -23.0% during the 2025 US Tariff Shock. Such a loss loss requires a 29.9% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About MAIA Biotechnology (MAIA)

    MAIA Biotechnology (MAIA) is a clinical-stage biopharmaceutical company focused on developing innovative targeted immunotherapies for cancer. Its lead asset, THIO (6-thio-2’-deoxyguanosine), is an investigational drug candidate with a dual mechanism of action, combining telomere targeting with immunogenicity. THIO is designed to disrupt cancer cell telomeres and transform immunologically "cold" tumors into "hot" tumors, thereby rendering them responsive to immune checkpoint inhibitors. MAIA initiated a Phase 2 clinical trial (THIO-101) in July 2022 for patients with advanced Non-Small Cell Lung Cancer (NSCLC), where THIO is administered in sequence with Regeneron’s PD-1 inhibitor, Libtayo® (cemiplimab).

    The company is primarily targeting patients with advanced cancers who have progressed on existing therapies or whose tumors are unresponsive to current immunotherapies. THIO is being developed as a second- or later line of treatment for NSCLC. Beyond NSCLC, MAIA plans to initiate a pivotal Phase 2 clinical trial by the end of 2023 for advanced colorectal cancer, hepatocellular carcinoma (HCC), and small cell lung cancer (SCLC), having already received Orphan Drug Designation from the FDA for HCC and SCLC. MAIA's strategy includes seeking accelerated FDA approval for THIO in advanced NSCLC in late 2024.

    In addition to THIO, MAIA is actively advancing a pipeline of second-generation small molecule telomere modifying agents. This early-stage research and discovery program aims to identify new compounds with potentially improved specificity and increased anticancer activity, with a goal of advancing at least one new compound to clinical trials by the end of 2024. The company is committed to addressing significant unmet medical needs in various solid tumor types by improving and restoring the efficacy of immunotherapy.

    AI Analysis | Feedback

    MAIA is like a biotech that develops 'sensitizer' drugs, similar to how a company like Regeneron develops their immunotherapies, but MAIA's drugs are designed to make difficult cancer tumors responsive to those existing immunotherapies.

    MAIA is like a specialist in making "cold" cancer tumors "hot," enabling powerful existing immunotherapies from companies like Merck or Bristol Myers Squibb to work effectively against them.

    MAIA is like a biotech focused on overcoming resistance to current cancer immunotherapies, creating a 'second chance' for patients whose tumors have progressed beyond treatments from companies like Regeneron or Merck.

    AI Analysis | Feedback

    • THIO (6-thio-dG or 6-thio-2’-deoxyguanosine): This is a lead investigational telomere-targeting immunotherapy drug candidate for advanced cancers, currently in Phase 2 clinical trials for Non-Small Cell Lung Cancer and holding Orphan Drug Designation for hepatocellular carcinoma and small cell lung cancer.
    • Second-generation telomere targeting agents: These are a pipeline of novel compounds in early-stage research and pre-clinical development, designed to improve upon THIO's mechanism of action for various cancer types.

    AI Analysis | Feedback

    Based on the provided background information, MAIA Biotechnology (symbol: MAIA) is a clinical-stage biopharmaceutical company. Its primary activity is the development of investigational drug candidates, such as THIO, which is currently undergoing Phase 2 clinical trials. The company has not yet received regulatory approval for any of its drug candidates and, therefore, is not currently engaged in the commercial sale of products.

    Consequently, MAIA Biotechnology does not have any major customers, either other companies or individual patients, as it is not yet selling commercial products.

    AI Analysis | Feedback

    • Regeneron Pharmaceuticals (REGN)

    AI Analysis | Feedback

    Vlad Vitoc, Chief Executive Officer, President, and Chairman

    Dr. Vitoc is a co-founder of MAIA Biotechnology, Inc., establishing the company in 2018. He is a seasoned biotech executive with an M.D. and an MBA. Prior to MAIA, he held leadership roles at other companies where he was instrumental in launching multi-billion dollar oncology drugs, including Tarceva for NSCLC at Astellas and XTANDI for prostate cancer.

    Jeffrey Himmelreich, Chief Financial Officer

    Mr. Himmelreich serves as the Chief Financial Officer, a position he was appointed to on November 9, 2023.

    Dr. Sergei M. Gryaznov, Chief Scientific Officer

    Dr. Gryaznov is the Chief Scientific Officer, leading MAIA's scientific vision and research and development initiatives. He is a distinguished scientist with extensive experience in biological research and drug discovery, and he is the inventor on the THIO patents.

    AI Analysis | Feedback

    1. Clinical Trial and Regulatory Approval Risk: MAIA Biotechnology's success hinges entirely on the successful outcome of its clinical trials for THIO, particularly the ongoing Phase 2 THIO-101 study in NSCLC and planned pivotal trials. There is no guarantee that THIO will achieve its intended clinical effect with a manageable safety profile, or that it will secure accelerated approval or full marketing approval from regulatory bodies like the FDA, even if granted expedited program designations. The trial design, statistical analysis, or endpoints may need modification, and safety and efficacy data generated might not be sufficient for approval.

    2. Dependence on Third-Party Collaboration and Supply: MAIA is dependent on a clinical supply agreement with Regeneron for cemiplimab (Libtayo®) at no cost. While this offers significant cost savings, it also means MAIA is reliant on Regeneron's continued supply of the drug. In return for this, MAIA has granted Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC for the study period, which could limit future opportunities.

    3. Intellectual Property and Competition Risk: While MAIA is developing "second-generation small molecule telomere modifying agents" and aims to strengthen its patent portfolio, the program is in early stages, and there's a risk they may not identify suitable compounds or successfully create a second generation of THIO-like compounds. Additionally, the biopharmaceutical landscape is highly competitive, and other therapies or companies could emerge with more effective or similarly acting treatments.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    MAIA Biotechnology's lead product candidate, THIO (ateganosine), is being developed for several cancer indications, each with a significant addressable market. For **Non-Small Cell Lung Cancer (NSCLC)**, the global market for NSCLC treatment was valued at $34.1 billion in 2024 and is projected to nearly double to $68.8 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 8.1%. The company also targets a population of approximately 50,000 U.S. patients annually for third-line NSCLC. The addressable market for **Hepatocellular Carcinoma (HCC)**, for which THIO has received Orphan Drug Designation, represents an estimated global sales market of $3.8 billion. For **Small Cell Lung Cancer (SCLC)**, another indication with Orphan Drug Designation for THIO, the estimated global sales market is $2.8 billion. In the case of **Colorectal Cancer**, the global market size was evaluated at $13 billion in 2023 and is projected to reach $20 billion by the end of 2032.

    AI Analysis | Feedback

    MAIA Biotechnology (NYSE American: MAIA) anticipates significant revenue growth over the next two to three years, primarily driven by the advancement and commercialization of its lead drug candidate, ateganosine (THIO). The key drivers include: * **Commercial Launch and Market Penetration of Ateganosine (THIO) for Non-Small Cell Lung Cancer (NSCLC).** MAIA Biotechnology has achieved FDA Fast Track designation for ateganosine in NSCLC in July 2025, expediting its development and review process. The company is pursuing accelerated approval and priority review pathways for ateganosine for advanced NSCLC that has progressed after immune checkpoint inhibitor therapy, with a potential FDA decision as early as 2026 or within 18 to 24 months from January 2026, meaning mid-2027 to early 2028. Positive efficacy data from the Phase 2 THIO-101 trial, demonstrating superior progression-free and overall survival compared to standard of care, supports these regulatory efforts. The initiation and enrollment of a pivotal Phase 3 trial (THIO-104) in third-line NSCLC patients, coupled with a high probability of technical success, positions ateganosine for potential early commercial approval in a targeted U.S. patient population of approximately 50,000 annually, within an estimated $50 billion global immunotherapy market. * **Expansion of Ateganosine into Additional Oncology Indications.** Beyond NSCLC, MAIA has secured FDA Orphan Drug Designations (ODDs) for ateganosine in hepatocellular carcinoma, small cell lung cancer, and glioblastoma. These designations offer seven years of U.S. market exclusivity upon regulatory approval, presenting substantial opportunities to broaden THIO's market reach to other difficult-to-treat cancers. The company has plans for multiple THIO trials in these additional cancer indications, which, upon successful clinical development and approval, will contribute significantly to future revenue streams. * **Geographic Market Expansion for Ateganosine.** MAIA Biotechnology is actively expanding the clinical development of THIO into new geographies. The THIO-101 Phase 2 clinical trial has advanced to a Part C expansion phase, significantly increasing the patient pool to include countries in Asia and Europe, in addition to Australia and the U.S. This strategic global expansion of its clinical trials is intended to support broader regulatory and commercial relevance, ultimately paving the way for international market entry and increased revenue generation for ateganosine in the coming years.

    AI Analysis | Feedback

    Share Repurchases

    • MAIA Biotechnology's Board of Directors approved a share repurchase program on September 28, 2023, authorizing the purchase of up to $800,000 of its Class A common stock through September 2024.

    Share Issuance

    • In July 2022, the company completed an Initial Public Offering (IPO), selling 2,000,000 shares of common stock at $5 per share for gross proceeds of $10,000,000. An additional 300,000 shares were sold on August 3, 2022, through an overallotment option, generating an extra $1,500,000 in gross proceeds.
    • In March 2026, MAIA Biotechnology completed an underwritten public offering of 20,000,000 shares at $1.50 per share, resulting in aggregate gross proceeds of $30,000,000.
    • The company conducted several private placements, including raising approximately $2.25 million in September 2025 from the sale of 1,733,766 shares of common stock at $1.30 per share.

    Inbound Investments

    • In February 2021, MAIA Biotechnology signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, leading to significant cost-savings for the THIO-101 study.
    • The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to THIO in March 2022 for hepatocellular carcinoma and in May 2022 for small cell lung cancer, which provides financial incentives and potential market exclusivity.

    Peer Outperformance in Biotechnology

    null
    Share of Biotechnology constituents that MAIA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    45%
    of 455 industry peers · -15.5% return
    3Y
    53%
    of 402 industry peers · -14.9% return
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is MAIA's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 16.2%43.2%90.1% CAH 392% · MCK 346% · COR 168%
    Managed Health Care 8 40.4%-5.3%2.3% OSCR 84% · HQY 56% · ELV 17%
    Health Care Services 20 21.1%37.6%-0.3% HIMS 239% · RDNT 173% · DGX 76%
    Health Care Facilities 24 6.0%6.5%-4.5% NHC 271% · THC 261% · ENSG 129%
    Health Care Equipment 50 -2.7%-0.2%-21.1% POCI 11050% · UFPT 341% · GKOS 222%
    Pharmaceuticals 62 -10.5%14.8%-38.6% LQDA 2472% · INDV 1099% · ETON 1051%
    Health Care Supplies 12 14.1%-8.9%-39.7% LNTH 287% · HAE 54% · MMSI 20%
    Life Sciences Tools & Services 109 4.3%-11.3%-68.4% SNWV 1757% · MEDP 231% · NTRA 199%
    Health Care Technology 21 -25.8%-52.6%-79.2% SPOK 68% · HSTM 3% · VEEV -13%
    Biotechnology ← 364 0.6%-21.7%-79.4% CELZ 1280% · DNTH 1221% · ELVN 1069%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1MAIA Biotechnology Earnings Notes12/16/2025
    Title
    0ARTICLES

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    SDGRSchrodinger2.252.6%62.3%
    PSPershing Square19.932.3%106.6%
    BBNXBeta Bionics1.032.1%-28.2%
    TEMTempus AI14.031.9%31.8%
    SECZSecuritize1.631.3%-11.7%
    TWSTTwist Bioscience10.431.3%426.5%
    EMATEvolution Metals & Technologies2.530.5%-81.1%
    GEMIGemini Space Station0.730.3%-41.4%
    RUMRumble2.626.8%43.8%
    ALMRAlamar Biosciences2.025.0%58.4%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    ADBTAdvasa0.1-47.1%-98.0%
    SWMRSwarmer0.4-39.4%-22.6%
    ALHCAlignment Healthcare1.7-33.8%-57.7%
    XENEXenon Pharmaceuticals4.0-32.2%-11.3%
    FLNCFluence Energy1.0-26.3%-63.0%
    ENVAEnova International4.3-21.8%11.1%
    VYXNCR Voyix0.9-21.2%-33.9%
    ARWRArrowhead Pharmaceuticals9.5-19.8%0.1%
    DMRADamora Therapeutics1.4-19.6%-1.8%
    IONSIonis Pharmaceuticals7.4-18.0%-43.8%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    SECZSecuritize1.680.1%-11.7%
    FWDIForward Industries0.755.9%16.5%
    PURRHyperliquid Strategies1.750.1%295.8%
    GEMIGemini Space Station0.747.8%-41.4%
    MSTRStrategy54.347.6%1.3%
    SMTCSemtech17.247.6%151.1%
    CVICVR Energy5.446.3%112.4%
    SDGRSchrodinger2.246.2%62.3%
    EMATEvolution Metals & Technologies2.541.1%-81.1%
    ACVAACV Auctions1.840.3%30.7%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ALMSAlumis1.0-67.6%-20.4%
    IESCIES12.8-47.5%-17.2%
    SWMRSwarmer0.4-46.9%-22.6%
    RAREUltragenyx Pharmaceutical1.5-44.7%-36.9%
    TTANServiceTitan5.2-42.1%-48.3%
    FLNCFluence Energy1.0-39.4%-63.0%
    KRMNKarman4.7-38.6%-51.1%
    XENEXenon Pharmaceuticals4.0-36.2%-11.3%
    DYNDyne Therapeutics2.8-36.1%-12.5%
    DKSDick's Sporting Goods10.7-36.1%-37.5%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    MAIAGERNTELOAGENIOVAREGNMedian
    NameMAIA Bio.Geron Telomir .Agenus Iovance .Regenero. 
    Mkt Price1.311.301.237.8510.25784.854.58
    Mkt Cap0.10.90.10.34.680.70.6
    Rev LTM0205013332515,535169
    Op Inc LTM-28-35-636-2964,174-17
    FCF LTM-23-115-5-99-2963,575-61
    FCF 3Y Avg-18-167-5-138-3403,439-78
    CFO LTM-23-114-5-99-2644,681-61
    CFO 3Y Avg-18-167-5-136-3194,498-77

    Growth & Margins

    MAIAGERNTELOAGENIOVAREGNMedian
    NameMAIA Bio.Geron Telomir .Agenus Iovance .Regenero. 
    Rev Chg LTM-24.4%-30.5%34.5%9.3%27.4%
    Rev Chg 3Y Avg-4,035.6%-18.3%4,780.4%7.0%2,026.9%
    Rev Chg Q-17.2%-34.4%65.7%16.7%25.8%
    QoQ Delta Rev Chg LTM-4.3%-7.1%13.8%4.1%5.7%
    Op Inc Chg LTM-42.7%54.4%62.4%139.2%27.9%6.1%41.2%
    Op Inc Chg 3Y Avg-17.6%29.9%-80.7%68.1%10.4%-1.7%4.3%
    Op Mgn LTM--17.2%-27.0%-91.1%26.9%4.8%
    Op Mgn 3Y Avg--5,541.4%--44.7%-554.2%28.2%-299.4%
    QoQ Delta Op Mgn LTM-0.6%-20.7%34.2%1.1%10.9%
    CFO/Rev LTM--55.9%--74.2%-81.3%30.1%-65.1%
    CFO/Rev 3Y Avg--5,092.6%--104.6%-464.4%31.2%-284.5%
    FCF/Rev LTM--56.1%--74.2%-91.2%23.0%-65.2%
    FCF/Rev 3Y Avg--5,118.8%--105.5%-482.4%23.9%-294.0%

    Valuation

    MAIAGERNTELOAGENIOVAREGNMedian
    NameMAIA Bio.Geron Telomir .Agenus Iovance .Regenero. 
    Mkt Cap0.10.90.10.34.680.70.6
    P/S-4.3-2.414.25.24.7
    P/Op Inc-2.8-24.7-12.39.0-15.619.3-7.6
    P/EBIT-2.9-23.3-12.72.1-15.615.5-7.8
    P/E-3.0-12.9-12.73.5-15.918.6-7.9
    P/CFO-3.5-7.6-15.2-3.3-17.517.2-5.6
    Total Yield-33.7%-7.8%-7.9%28.4%-6.3%5.8%-7.0%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.5%0.0%
    FCF Yield 3Y Avg-25.0%-13.3%-6.5%-76.7%-29.9%4.9%-19.1%
    D/E0.00.10.00.10.00.00.0
    Net D/E-0.3-0.2-0.10.1-0.0-0.1-0.1

    Returns

    MAIAGERNTELOAGENIOVAREGNMedian
    NameMAIA Bio.Geron Telomir .Agenus Iovance .Regenero. 
    1M Rtn-5.8%-14.5%8.8%-3.0%23.6%-5.9%-4.4%
    3M Rtn-6.4%3.2%-13.4%161.7%162.1%28.8%16.0%
    6M Rtn-10.3%-11.0%-6.8%111.6%177.8%7.4%0.3%
    12M Rtn-15.5%-1.5%-19.6%79.2%400.0%33.3%15.9%
    3Y Rtn-14.9%-40.1%-75.4%-67.0%103.6%-3.8%-27.5%
    1M Excs Rtn-5.0%-17.5%5.9%-4.2%29.0%-5.9%-4.6%
    3M Excs Rtn-8.4%1.2%-15.4%159.7%160.1%26.8%14.0%
    6M Excs Rtn-28.5%-31.9%-22.6%90.2%149.1%-9.1%-15.9%
    12M Excs Rtn-30.8%-13.5%-23.4%56.6%345.8%18.8%2.6%
    3Y Excs Rtn-95.1%-113.5%-146.7%-141.1%17.3%-75.4%-104.3%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/10/20265/11/20263/23/202611/7/20258/11/20255/9/20253/21/202511/12/20248/9/20245/14/20243/21/202411/7/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-8-7-4-9-5-5-4-3-4-4-6-5
    Operating Income-8-7-4-9-5-5-5-4-4-4-6-5
    Net Income-8-6-4-9-5-5-4-3-9-8-6-5
    EPS-0.13-0.14-0.08-0.27-0.18-0.16-0.12-0.11-0.40-0.46-0.41-0.36
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-27-24-23-23-17-16-14-17-19-20-20-18
    Operating Income TTM-28-25-24-25-20-18-17-18-19-20-20-18
    Net Income TTM-27-24-22-22-16-20-23-26-28-24-20-18
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-57.0%-24.2%-1.6%-225.4%-36.0%-38.0%42.9%43.9%16.0%4.4%-51.1%0.5%
    Operating Income Growth-57.0%-24.2%20.5%-124.3%-36.0%-38.0%21.6%14.8%17.9%4.9%-54.5%2.6%
    Net Income Growth-48.6%-41.0%-1.6%-225.4%39.8%44.0%42.9%43.9%-96.3%-96.0%-50.9%0.6%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash2834911101110912876
    Total Debt000000000000
    Net Debt / (Cash)-28-34-9-11-10-11-10-9-12-8-7-6
    Cash Flows Quarterly            
    FCF from Operations-7-5-7-3-4-4-4-4-5-4-4-3
    Cash Flows TTM            
    FCF from Operations TTM-23-20-19-16-16-16-16-16-15-13-13-12
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-27.7%-24.6%-15.3%-39.4%-22.8%-25.3%-24.5%-21.8%-20.9%-27.1%-44.3%-36.0%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-24.1%-23.1%-23.1%-26.2%-21.7%-21.4%-20.8%-23.8%-26.2%-34.1%-34.9%-32.7%

    Segment Financials

    Assets by Segment
    $ Mil20252024202320222021
    Business of discovering and developing products for the treatment of immunotherapies for cancer101081211
    Total101081211


    Price Behavior

    Price Behavior
    Market Price$1.31 
    Market Cap ($ Bil)0.1 
    First Trading Date07/28/2022 
    Distance from 52W High-55.6% 
       50 Days200 Days
    DMA Price$1.35$1.50
    DMA Trendupindeterminate
    Distance from DMA-2.8%-12.5%
     3M1YR
    Volatility47.9%89.2%
    Downside Capture142.34178.28
    Upside Capture92.23128.42
    Correlation (SPY)34.5%25.0%
    MAIA Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta1.812.021.852.091.820.89
    Up Beta2.252.422.952.982.680.88
    Down Beta2.452.092.263.071.541.20
    Up Capture158%133%113%62%169%30%
    Bmk +ve Days10213268138427
    Stock +ve Days8162654118351
    Down Capture138%236%143%189%151%97%
    Bmk -ve Days11213259113324
    Stock -ve Days11223160114355

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MAIA
    MAIA-15.0%88.7%0.22-
    Sector ETF (XLV)24.4%16.1%1.1611.5%
    Equity (SPY)16.9%12.9%0.9425.0%
    Gold (GLD)19.1%29.3%0.6023.0%
    Commodities (DBC)46.3%20.6%1.732.1%
    Real Estate (VNQ)4.9%13.6%0.107.5%
    Bitcoin (BTCUSD)-30.6%44.3%-0.7017.1%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MAIA
    MAIA-21.2%92.7%0.11-
    Sector ETF (XLV)6.4%15.2%0.247.1%
    Equity (SPY)12.9%17.2%0.5711.6%
    Gold (GLD)19.1%18.8%0.837.8%
    Commodities (DBC)11.2%19.5%0.453.9%
    Real Estate (VNQ)1.1%18.8%-0.056.9%
    Bitcoin (BTCUSD)12.5%52.5%0.424.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MAIA
    MAIA-11.2%92.7%0.11-
    Sector ETF (XLV)10.6%16.7%0.517.1%
    Equity (SPY)15.1%18.0%0.7211.6%
    Gold (GLD)12.1%16.4%0.617.8%
    Commodities (DBC)8.3%18.1%0.373.9%
    Real Estate (VNQ)4.4%20.7%0.186.9%
    Bitcoin (BTCUSD)62.6%66.2%1.024.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8312026
    Short Interest: Shares Quantity2.3 Mil
    Short Interest: % Change Since 8152026-14.6%
    Average Daily Volume0.4 Mil
    Days-to-Cover Short Interest6.4 days
    Basic Shares Quantity60.8 Mil
    Short % of Basic Shares3.9%

    Earnings Returns History

    Updated 6/2/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    11/7/20234.2%-19.4%-56.5%
    8/8/20230.0%-2.4%-11.0%
    5/8/2023-6.7%-12.3%-15.5%
    11/9/2022-5.6%4.2%-2.8%
    8/22/20226.3%-3.5%-16.5%
    SUMMARY STATS   
    # Positive310
    # Negative245
    Median Positive4.2%4.2% 
    Median Negative-6.1%-7.9%-15.5%
    Max Positive6.3%4.2% 
    Max Negative-6.7%-19.4%-56.5%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    11/7/20234.2%-19.4%-56.5%
    8/8/20230.0%-2.4%-11.0%
    5/8/2023-6.7%-12.3%-15.5%
    11/9/2022-5.6%4.2%-2.8%
    8/22/20226.3%-3.5%-16.5%
    SUMMARY STATS   
    # Positive310
    # Negative245
    Median Positive4.2%4.2% 
    Median Negative-6.1%-7.9%-15.5%
    Max Positive6.3%4.2% 
    Max Negative-6.7%-19.4%-56.5%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/10/202610-Q
    03/31/202605/11/202610-Q
    12/31/202503/23/202610-K
    09/30/202511/07/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/09/202510-Q
    12/31/202403/21/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/09/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/21/202410-K
    09/30/202311/07/202310-Q
    06/30/202308/08/202310-Q
    03/31/202305/08/202310-Q
    12/31/202203/24/202310-K
    09/30/202211/09/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/10/202610-Q
    03/31/202605/11/202610-Q
    12/31/202503/23/202610-K
    09/30/202511/07/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/09/202510-Q
    12/31/202403/21/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/09/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/21/202410-K
    09/30/202311/07/202310-Q
    06/30/202308/08/202310-Q
    03/31/202305/08/202310-Q
    12/31/202203/24/202310-K
    09/30/202211/09/202210-Q
    06/30/202208/22/202210-Q
    03/31/202207/29/2022424B4
    09/30/202102/06/202310-Q/A

    Insider Activity

    Updated 9/14/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Guerrero, Ramiro DirectBuy91420261.3237,59549,5161,018,508Form
    2Guerrero, Ramiro DirectBuy90120261.3546,62062,937993,196Form
    3Guerrero, Ramiro DirectBuy90120261.3978,239108,752957,823Form
    4Guerrero, Ramiro DirectBuy90120261.398,93112,414849,070Form
    5Guerrero, Ramiro DirectBuy82620261.331,7942,386800,542Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Guerrero, Ramiro DirectBuy91420261.3237,59549,5161,018,508Form
    2Guerrero, Ramiro DirectBuy90120261.3546,62062,937993,196Form
    3Guerrero, Ramiro DirectBuy90120261.3978,239108,752957,823Form
    4Guerrero, Ramiro DirectBuy90120261.398,93112,414849,070Form
    5Guerrero, Ramiro DirectBuy82620261.331,7942,386800,542Form
    6Guerrero, Ramiro DirectBuy82420261.3711,89916,302822,160Form
    7Vitoc, VladChief Executive OfficerDirectBuy60220261.3972,700100,8861,354,563Form
    8Smith, Stan See FootnoteBuy60220261.3475,000100,2002,029,622Form
    9Gryaznov, SergeiChief Scientific OfficerDirectBuy60220261.342,0002,69062,557Form
    10Smith, Stan See FootnoteBuy11220263.692,7009,9595,252,938Form
    11Smith, Stan See FootnoteBuy122220251.2257,18969,9991,739,889Form
    12Chaouki, Steven M DirectBuy122220251.2240,84949,999185,893Form
    13Louie, Ngar Yee DirectBuy122220251.2281,699100,0001,528,639Form
    14Smith, Stan See footnoteBuy120920251.2013,74016,4415,480Form
    15Vitoc, VladChief Executive OfficerDirectBuy112820251.1450,00056,8301,001,823Form
    16Luput, Cristian DirectBuy112820251.1118,14520,230487,911Form
    17Vitoc, VladChief Executive OfficerDirectBuy112820251.0522,00023,019892,934Form
    18Luput, Cristian DirectBuy112820251.0820,00021,616453,377Form
    19Smith, Stan See FootnoteBuy112820251.0415,00015,5821,417,223Form
    20Luput, Cristian DirectBuy112620250.9810,0009,785390,894Form
    21Vitoc, VladChief Executive OfficerDirectBuy112620250.9710,50010,144803,236Form
    22Smith, Stan See FootnoteBuy112620250.9815,00014,7001,322,303Form
    23Smith, Stan See FootnoteBuy112620250.9910,0009,9001,320,946Form
    24Vitoc, VladChief Executive OfficerDirectBuy112520250.9910,0009,891811,973Form
    25Vitoc, VladChief Executive OfficerDirectBuy112520250.921,8001,656746,047Form
    26Smith, Stan See FootnoteBuy100220251.3019,23024,9991,721,576Form

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/20/2026